452 related articles for article (PubMed ID: 30044517)
1. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals.
Sugiura A; Joshita S; Umemura T; Yamazaki T; Fujimori N; Kimura T; Matsumoto A; Igarashi K; Usami Y; Wada S; Mori H; Shibata S; Yoshizawa K; Morita S; Furuta K; Kamijo A; Iijima A; Kako S; Maruyama A; Kobayashi M; Komatsu M; Matsumura M; Miyabayashi C; Ichijo T; Takeuchi A; Koike Y; Gibo Y; Tsukadaira T; Inada H; Kiyosawa K; Tanaka E
J Viral Hepat; 2018 Dec; 25(12):1462-1471. PubMed ID: 30044517
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
4. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C.
Yoshimasu Y; Furuichi Y; Kasai Y; Takeuchi H; Sugimoto K; Nakamura I; Itoi T
J Gastrointestin Liver Dis; 2019 Mar; 28(1):63-71. PubMed ID: 30851174
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
7. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
[TBL] [Abstract][Full Text] [Related]
8. Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy.
Wu CK; Chang KC; Hung CH; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hu TH
J Antimicrob Chemother; 2016 Jul; 71(7):1943-7. PubMed ID: 27073265
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
10. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.
Masetti C; Lionetti R; Lupo M; Siciliano M; Giannelli V; Ponziani FR; Teti E; Dell'Unto C; Francioso S; Brega A; Montalbano M; Visco-Comandini U; Taibi C; Galati G; Vespasiani Gentilucci U; Picardi A; Andreoni M; Pompili M; Pellicelli AM; D'Offizi G; Gasbarrini A; De Santis A; Angelico M
J Viral Hepat; 2018 Dec; 25(12):1493-1500. PubMed ID: 30112854
[TBL] [Abstract][Full Text] [Related]
11. Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients.
Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Luo JC; Lee IC; Chi CT; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2024 Apr; 87(4):357-368. PubMed ID: 38180018
[TBL] [Abstract][Full Text] [Related]
12. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
[TBL] [Abstract][Full Text] [Related]
14. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents.
Huang CM; Hu TH; Chang KC; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hung CH; Cho CL; Wu CK
Medicine (Baltimore); 2017 Nov; 96(46):e8696. PubMed ID: 29145306
[TBL] [Abstract][Full Text] [Related]
15. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
16. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
17. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH
Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552
[TBL] [Abstract][Full Text] [Related]
18. Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.
Ogata F; Kobayashi M; Akuta N; Osawa M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Suzuki F; Arase Y; Ikeda K; Kumada H
Oncology; 2017; 93(2):92-98. PubMed ID: 28448999
[TBL] [Abstract][Full Text] [Related]
19. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
[TBL] [Abstract][Full Text] [Related]
20. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
Roche B; Coilly A; Duclos-Vallee JC; Samuel D
Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
